Most investors have never heard of ABC arbitrage. The Paris-listed group is a specialist proprietary-trading and asset-management firm that makes money from tiny, fleeting price discrepancies across global markets — statistical andMergerarbitrage, rather than directional bets. Its pitch is unusual: it claims 31 consecutive …
On 6 August 2026, 10x Genomics (NASDAQ:TXG) reported second-quarter results and nudged up its full-yearRevenueguidance, crediting what chief executive Serge Saxonov called "the extraordinary customer response" to Atera, its newest spatial-biology platform, launched in April. Headline revenue actually fell year on year, yet the …
For much of the past three years, AbbVie's story has been dominated by one word: Humira. The world's best-selling drug lost US exclusivity in 2023, and the resultingRevenuedecline — the so-called 'Humira hangover' — has shadowed the stock ever since. AbbVie's second-quarter 2026 results, …
Gene therapy has long promised medical miracles and delivered financial heartache — spectacular science paired with spectacular cash burn. Abeona Therapeutics is trying to buck that pattern. Its ZEVASKYN, a one-time autologous cell-sheet therapy for the devastating skin disease recessive dystrophic epidermolysis bullosa (RDEB), …
When Abbott Laboratories reported second-quarter 2026Earningson 16 July, the market's reaction was emphatic. The shares jumped sharply — press coverage described the move as Abbott's best single day in around 24 years — as the Illinois-based group beat profit expectations and lifted its full-year …
Liquidia has recently outperformed sales expectations, providing a significant boost in its competitive stance against United Therapeutics. The company's remarkable sales growth highlights its strong market presence, particularly notable as investors scrutinize the ever-evolving biotech environment. Liquidia's performance is especially critical given the industry's …
GENinCode PLC has moved sharply into focus afterLSE:GENI fell 10.53% on 12 August 2026.
Kyntra Bio, the renamed FibroGen, has slimmed down into a focused cancer developer with roughly $100m of cash and one looming data readout. For patient risk-takers, a single fourth-quarter milestone could redefine the story.
Arecor has spent a decade turning formulation science into better medicines. Non-dilutive funding, a marquee insulin-deliveryPartnershipand a pivotal Phase 2 trial now loom. With biotech financing thawing, could this £22m minnow reclaim investor attention?
RUA Life Sciences PLC LSE:RUA is in focus on12 August 2026 after its shares gained 13.88%, putting the specialist medical-device company among the strongest healthcare movers in the UK small-cap market.